Company: TVRD
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001104659-25-054853
Chunk: 303

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 303
---
 Vendor A |   |                      62 | % |   33 | % |                    43 | % |   40 | % |
| Vendor B |   |                       1 | % |   14 | % |                     2 | % |    — | ​ |
| Vendor C |   |                       3 | % |    8 | % |                     8 | % |   10 | % |
| Vendor D |   |                       — |   |    — |   |                     — |   |   19 | % |
| ​        |   |                      66 | % |   55 | % |                    53 | % |   69 | % |

The Company’s preclinical studies and clinical trials and testing could be adversely affected by a significant interruption in the supply chain from its significant suppliers.

Cash and Cash Equivalents

The Company considers all highly liquid investments, with an original maturity of three months or less, to be cash equivalents. Cash equivalents include amounts held in money market funds in the amount of $ million and $ million as of December 31, 2024 and 2023, respectively.

The Company recorded interest income on its cash equivalents of $ million for the year ended December 31, 2024 on its statements on operations. The Company recorded interest income of $ million on its cash equivalents and previously outstanding short-term investments during the year ended December 31, 2023 on its statements of operations. The interest income recorded during the year ended December 31, 2023 is also inclusive of accretion of its discounts on its short-term investments, which fully matured during the year ended December 31, 2023.

F-10

Deferred Offering Costs

The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholders’ deficit as a reduction of additional paid-in-capital generated as a result of the offering. Should the planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations. The Company recorded deferred offering costs of $ million and $ as of December 31, 2024 and 2023, respectively.

Fair Value Measurements

Certain assets